AYTU
MaterialsAytu BioPharma Inc
Live · NASDAQ · May 9, Close
What's Moving AYTU Today?
No stock-specific AI insight has been generated for AYTU yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
AYTU News
20 articles- Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026Yahoo Finance·May 6, 2026
- Favourable Signals For Aytu BioPharma: Numerous Insiders Acquired StockYahoo Finance·Apr 30, 2026
- Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To ProfitYahoo Finance·Feb 5, 2026
- Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ...Yahoo Finance·Feb 4, 2026
- Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue EstimatesYahoo Finance·Feb 3, 2026
- Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial ResultsYahoo Finance·Feb 3, 2026
- New Strong Sell Stocks for February 2ndYahoo Finance·Feb 2, 2026
- Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026Yahoo Finance·Jan 27, 2026
- Aytu BioPharma Recaps Investor Day Held on January 20, 2026Yahoo Finance·Jan 20, 2026
- Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUAYahoo Finance·Jan 20, 2026
- Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026Yahoo Finance·Jan 13, 2026
- Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York CityYahoo Finance·Jan 12, 2026
- Aytu BioPharma to Host Investor Day on January 20, 2026 in New York CityYahoo Finance·Dec 18, 2025
- Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in AdultsYahoo Finance·Dec 15, 2025
- Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceYahoo Finance·Nov 24, 2025
- Positive Signs As Multiple Insiders Buy Aytu BioPharma StockYahoo Finance·Nov 21, 2025
- Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ...Yahoo Finance·Nov 14, 2025
- Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Nov 13, 2025
- Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial ResultsYahoo Finance·Nov 13, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Aytu BioPharma Inc
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.